Sanfarm, a company operating in the Tarnobrzeg Economic Zone in Poland, has become part of leading Polish drugmaker Zakłady Farmaceutyczne Polpharma SA.
The merger between the two companies was followed by the establishment of the Polpharma manufacturing division in Nowa Dęba which will be responsible for pharmaceutical production tasks, both for Polpharma Group companies and for third parties. All Sanfarm staff has been hired in the new division, while the former president of the company, Ryszard Latawiec, was appointed the division head.
The formal merger will contribute to a closer integration of the companies’ operations. It will bring notable benefits thanks to the synergy effect, among other things, in purchase processes relating to raw materials, packaging materials or utilities, says Polpharma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze